000			03328nam a22004215i 4500
001			82382
003			ES-MaUEC
005			20230207040409.0
007			cr nn 008mamaa
008			150716s2015 gw | s |||| 0|eng d
020			_a9783319173627
024	7		_a10.1007/978-3-319-17362-7 _2doi
050		4	_aRC935.M7 _b2015 EB
082	0	4	_a616.8
245	1	0	_aMuscular Dystrophy : _bA Concise Guide _cedited by Raymond A. Huml.
260			_aCham, Switzerland _bSpringer _c2015
300			_a1 recurso en línea (XXIV, 191 p.) _b43 ilustraciones, 30 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_a1. Introduction to Muscular Dystrophy -- 2.Muscular Dystrophy: Historical Background and Types -- 3.FSHD: The Most Common Type of MD? -- 4.Duchenne and Becker Muscular Dystrophies: Underlying Genetic and Molecular Mechanisms -- 5.An Overview of the Muscular Dystrophies: Underlying Genetic and Molecular Mechanisms -- 6.Transition from Childhood to Adult in Patients with Muscular Dystrophy -- 7.Overview of Current Treatments for Muscular Dystrophy -- 8.Physical Therapy and Orthotic Devices for Patients with Muscular Dystrophy -- 9.Orthopedic Care of Children with Muscular Dystrophy -- 10.Global Regulatory Landscape -- 11.Key Challenges to the Approval of Products to Treat Patients with Muscular Dystrophy -- 12.Pharmaceutical Products and Non-Pharmaceutical Interventions as Potential Treatments for Patients with Muscular Dystrophy -- 13.US Patient Advocacy Groups -- 14.Global and National Patient Registries -- 15.Summary -- Index.
520			_aThis practical and concise guide offers an overview of muscular dystrophy's (MD) complicated features, treatment options and general resources.ÂYw treatments and a greater understanding of proteins and structures associated with MD are discussed along with long-term patient care.Â{u006C}so included are clinical and developmental challenges within the current regulatory landscape and recent scientific and clinical advances.Â4scular Dystrophy: A Concise Guide offers clinicians, researchers, pharmaceutical executives and patient advocacy groups an easy-to-read reference that provides the necessary perspectives of the care giver and patient.
710	2		_aSpringerLink (Online service) _0Local _9106996
942			_2lcc _cLE
650		7	_aFarmacoterapia _0LocalX _2embne _9671142
650	2	7	_aFarmacoterapia _0LocalX _2embne _9671142
650	1	7	_aSalud pública _0LocalX _2embne _9138408
650	2	7	_aSalud pública _0LocalX _2embne _9138408
650		7	_aMedicina _0LocalX _2embne _9405021
650		7	_aNeurología _0LocalX _2embne _9139040
650	2	7	_aNeurología _0LocalX _2embne _9139040
700	1		_aHuml, Raymond A. _eeditor literario _0Local _995280
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-17362-7 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12910223 _b10-10-17 _c10-02-16
988			_aSpringer_Medicine_2015
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _ggw _h0
945			_aRC935.M7 M873 2015 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11577903 _z06-04-17
999			_c82382 _d82382 _x1